Acute Chest Syndrome Clinical Trial
Utility of the Cardiac Electrical Biomarker in Patients With Ischaemic Heart Disease
|Source||Milton Keynes University Hospital NHS Foundation Trust|
|Phone||0044 1908 995136|
|Start date||May 22, 2017|
|Completion date||December 1, 2019|
This project is aiming to identify the diagnostic utility CEB (Cardiac Electrical Biomarker) in patients who are undergoing cardiac investigations.
This project is aiming to identify the diagnostic utility of an ECG derived measurement by a
Medical device (Vectraplex by VectraCor ltd) in patients who are undergoing cardiac
investigations. This technology is based on the principle of vector ECG and an analysing
system that computes a composite score termed a Cardiac Electrical Biomarker (CEB TM).
CEB has been validated in the detection of STEMI with high sensitivity and specificity in the detection ECG changes characteristic to STEMI. The CEB may be a more accurate way of identifying heart injury and causes of chest pain compared to standard tests, which could lead to faster diagnosis and treatment of these patients.
The diagnostic utility of the CEBTM in the following:
1. Acute chest pain assessment in the A&E department.
2. Acute chest pain assessment in the Primary Care Surgery.
3. Performance of CEB during inducible ischaemia in patients with stable angina
4. Performance of CEB during acute ischaemia in patients undergoing percutaneous coronary intervention (PCI)
5. Performance of CEB in patients undergoing cardio-toxic treatment
|Not yet recruiting||
|Active, not recruiting||
||Phase 2/Phase 3|